UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option.

Our first product, JELMYTO^® (mitomycin) for pyelocalyceal solution, is approved for adult patients with low-grade upper tract urothelial cancer, and our second product, ZUSDURI^® (mitomycin) for intravesical solution, is approved for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both of our products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X (Twitter), @UroGenPharma.